Regenerative medicine based applications to combat stress urinary incontinence
- PMID: 24179600
- PMCID: PMC3812516
- DOI: 10.4252/wjsc.v5.i4.112
Regenerative medicine based applications to combat stress urinary incontinence
Abstract
Stress urinary incontinence (SUI), as an isolated symptom, is not a life threatening condition. However, the fear of unexpected urine leakage contributes to a significant decline in quality of life parameters for afflicted patients. Compared to other forms of incontinence, SUI cannot be easily treated with pharmacotherapy since it is inherently an anatomic problem. Treatment options include the use of bio-injectable materials to enhance closing pressures, and the placement of slings to bolster fascial support to the urethra. However, histologic findings of degeneration in the incontinent urethral sphincter invite the use of tissues engineering strategies to regenerate structures that aid in promoting continence. In this review, we will assess the role of stem cells in restoring multiple anatomic and physiological aspects of the sphincter. In particular, mesenchymal stem cells and CD34(+) cells have shown great promise to differentiate into muscular and vascular components, respectively. Evidence supporting the use of cytokines and growth factors such as hypoxia-inducible factor 1-alpha, vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor and insulin-like growth factor further enhance the viability and direction of differentiation. Bridging the benefits of stem cells and growth factors involves the use of synthetic scaffolds like poly (1,8-octanediol-co-citrate) (POC) thin films. POC scaffolds are synthetic, elastomeric polymers that serve as substrates for cell growth, and upon degradation, release growth factors to the microenvironment in a controlled, predictable fashion. The combination of cellular, cytokine and scaffold elements aims to address the pathologic deficits to urinary incontinence, with a goal to improve patient symptoms and overall quality of life.
Keywords: Angiogenesis; Biomaterials; Regeneration; Smooth muscle; Sphincter; Stem cells; Stress urinary incontinence; Tissue engineering.
Figures
Similar articles
-
Midurethral slings for women with stress urinary incontinence: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(3):1-61. Epub 2006 Feb 1. Ont Health Technol Assess Ser. 2006. PMID: 23074494 Free PMC article.
-
Cell Therapy for Stress Urinary Incontinence.Tissue Eng Part B Rev. 2015 Aug;21(4):365-76. doi: 10.1089/ten.TEB.2014.0627. Epub 2015 Apr 22. Tissue Eng Part B Rev. 2015. PMID: 25789845 Review.
-
Microfluidic production of bioactive fibrin micro-beads embedded in crosslinked collagen used as an injectable bulking agent for urinary incontinence treatment.Acta Biomater. 2018 Feb;67:156-166. doi: 10.1016/j.actbio.2017.11.034. Epub 2017 Nov 29. Acta Biomater. 2018. PMID: 29197579
-
Applicability of regenerative medicine and tissue engineering for the treatment of stress urinary incontinence in female patients.Neurourol Urodyn. 2019 Aug;38 Suppl 4:S76-S83. doi: 10.1002/nau.24033. Epub 2019 May 16. Neurourol Urodyn. 2019. PMID: 31099087 Review.
-
Transcriptomic Analysis of Human Mesenchymal Stem Cell Therapy in Incontinent Rat Injured Urethra.Tissue Eng Part A. 2020 Jul;26(13-14):792-810. doi: 10.1089/ten.tea.2020.0033. Epub 2020 Jul 2. Tissue Eng Part A. 2020. PMID: 32614683 Free PMC article.
Cited by
-
BMSCs-EVs Alleviate Pelvic Floor Dysfunction in Mice by Reducing Inflammation and Promoting Tissue Regeneration.In Vivo. 2024 Nov-Dec;38(6):2680-2687. doi: 10.21873/invivo.13745. In Vivo. 2024. PMID: 39477385 Free PMC article.
-
Microenergy shockwave therapies for female stress urinary incontinence.Transl Androl Urol. 2024 Aug 31;13(8):1687-1694. doi: 10.21037/tau-23-9. Epub 2023 Aug 21. Transl Androl Urol. 2024. PMID: 39280672 Free PMC article. Review.
-
Treatment of stress urinary incontinence with low-intensity extracorporeal shock wave therapy in a vaginal balloon dilation induced rat model.Transl Androl Urol. 2018 Mar;7(Suppl 1):S7-S16. doi: 10.21037/tau.2017.12.36. Transl Androl Urol. 2018. PMID: 29644165 Free PMC article.
-
Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells.Stem Cells Transl Med. 2020 Dec;9(12):1500-1508. doi: 10.1002/sctm.19-0431. Epub 2020 Aug 31. Stem Cells Transl Med. 2020. PMID: 32864818 Free PMC article. Clinical Trial.
-
Ca2+ signalling in mouse urethral smooth muscle in situ: role of Ca2+ stores and Ca2+ influx mechanisms.J Physiol. 2018 Apr 15;596(8):1433-1466. doi: 10.1113/JP275719. J Physiol. 2018. PMID: 29383731 Free PMC article.
References
-
- Kapoor DS, Meher S, Watkins L, Das M. Referral patterns for pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:1469–1472. - PubMed
-
- Stothers L, Friedman B. Risk factors for the development of stress urinary incontinence in women. Curr Urol Rep. 2011;12:363–369. - PubMed
-
- Milsom I. Lower urinary tract symptoms in women. Curr Opin Urol. 2009;19:337–341. - PubMed
-
- Strasser H, Tiefenthaler M, Steinlechner M, Eder I, Bartsch G, Konwalinka G. Age dependent apoptosis and loss of rhabdosphincter cells. J Urol. 2000;164:1781–1785. - PubMed
-
- Brown SJ, Gartland D, Donath S, MacArthur C. Effects of prolonged second stage, method of birth, timing of caesarean section and other obstetric risk factors on postnatal urinary incontinence: an Australian nulliparous cohort study. BJOG. 2011;118:991–1000. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources